CLAIMS

1. A compound of Formula (I):



Formula (I)

wherein:

A is (C_{5-6})cycloalkyldiyl, cyclic heteroalkyldiyl, aryldiyl or heteroaryldiyl;

B is aryldiyl or heteroaryldiyl;

E is aryldiyl or heteroaryldiyl;

R_1 is (C_{3-8})cycloalkyl-(R_8)$_q$, cyclic heteroalkyl-(R_9)$_q$, aryl-(R_8)$_q$, heteroaryl-(R_9)$_q$ or NR_5R_6;

R_5 is hydrogen, (C_{1-12})alkanyl-R_7, C(O)H, C(O)-(C_{1-12})alkanyl-R_7, CO_2H, C(O)O-(C_{1-12})alkanyl-R_7, (C_{3-8})cycloalkyl-(R_8)$_q$, cyclic heteroalkyl-(R_9)$_q$, aryl-(R_8)$_q$ or heteroaryl-(R_9)$_q$; wherein cyclic heteroalkyl-(R_9)$_q$ and heteroaryl-(R_9)$_q$ are attached to the nitrogen atom of NR_5R_6 via a ring carbon atom;

R_6 is hydrogen or (C_{1-8})alkanyl-R_7;

R_7 is hydrogen, (C_{1-8})alkoxy-(R_{10})$_s$, C(O)H, C(O)-(C_{1-8})alkanyl-(R_{10})$_s$, C(O)-R_a, CO_2H, C(O)O-(C_{1-8})alkanyl-(R_{10})$_s$, C(O)O-R_a, OC(O)-(C_{1-8})alkanyl-(R_{10})$_s$, OC(O)-R_a, NH_2, NH(C_{1-8}alkanyl-(R_{10})$_s$), N(C_{1-8}alkanyl-(R_{10})$_s$)$_2$, cyano, (halo)$_{1-3}$, hydroxy or R_a;

R_a is (C_{3-8})cycloalkyl-$(R_{11})_q$, cyclic heteroalkyl-$(R_{12})_q$, aryl-$(R_{11})_q$ or heteroaryl-$(R_{12})_q$;

$(R_8)_q$ is hydrogen, (C_{1-8})alkanyl-$(R_{10})_s$, (C_{1-8})alkoxy-$(R_{10})_s$, C(O)H, C(O)-(C_{1-8})alkanyl-$(R_{10})_s$, CO_2H, C(O)O-(C_{1-8})alkanyl-$(R_{10})_s$, NH_2, $NH(C_{1-8}$alkanyl-$(R_{10})_s)$, $N(C_{1-8}$alkanyl-$(R_{10})_s)_2$ or halogen;

$(R_9)_q$ is hydrogen, (C_{1-8})alkanyl-$(R_{10})_s$, C(O)H, C(O)-(C_{1-8})alkanyl-$(R_{10})_s$, CO_2H or C(O)O-(C_{1-8})alkanyl-$(R_{10})_s$ when attached to a nitrogen atom; wherein $(R_9)_q$ is hydrogen, (C_{1-8})alkanyl-$(R_{10})_s$, (C_{1-8})alkoxy-$(R_{10})_s$, C(O)H, C(O)-(C_{1-8})alkanyl-$(R_{10})_s$, CO_2H, C(O)O-(C_{1-8})alkanyl-$(R_{10})_s$, NH_2, $NH(C_{1-8}$alkanyl-$(R_{10})_s)$, $N(C_{1-8}$alkanyl-$(R_{10})_s)_2$ or halogen when attached to a carbon atom;

$(R_{10})_s$ is hydrogen, (C_{1-8})alkoxy, NH_2, $NH(C_{1-8}$alkanyl), $N(C_{1-8}$alkanyl$)_2$, $(halo)_{1-3}$ or hydroxy;

$(R_{11})_q$ is hydrogen, (C_{1-8})alkanyl, (C_{1-8})alkoxy, NH_2, $NH(C_{1-8}$alkanyl), $N(C_{1-8}$alkanyl$)_2$ or halogen;

$(R_{12})_q$ is hydrogen or (C_{1-8})alkanyl;

R_2 is hydrogen, (C_{1-8})alkanyl-R_7, (C_{1-8})alkoxy-R_7, C(O)H, C(O)-(C_{1-8})alkanyl-R_7, CO_2H, C(O)O-(C_{1-8})alkanyl-R_7, NH_2, $NH(C_{1-8}$alkanyl-$R_7)$, $N(C_{1-8}$alkanyl-$R_7)_2$, cyano, halogen, hydroxy or R_a;

R_3 and R_4 are independently hydrogen, (C_{1-8})alkanyl-R_7, C(O)H, C(O)-(C_{1-8})alkanyl-R_7, CO_2H, C(O)O-(C_{1-8})alkanyl-R_7, (C_{3-8})cycloalkyl-$(R_8)_q$ or aryl-$(R_8)_q$ when attached to a nitrogen atom; wherein R_3 and R_4 are independently hydrogen, (C_{1-8})alkanyl-R_7, (C_{1-8})alkoxy-R_7, C(O)H, C(O)-(C_{1-8})alkanyl-R_7, CO_2H, C(O)O-(C_{1-8})alkanyl-R_7, NH_2, $NH(C_{1-8}$alkanyl-$R_7)$, $N(C_{1-8}$alkanyl-$R_7)_2$, cyano, halogen, hydroxy,

(C_{3-8})cycloalkyl-$(R_8)_q$, cyclic heteroalkyl-$(R_9)_q$, aryl-$(R_8)_q$ or heteroaryl-$(R_9)_q$ when attached to a carbon atom;

q is 1, 2, 3, 4 or 5; and,

s is 1 or 2;

and enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein A is aryldiyl.

3. The compound of claim 1 wherein A is benzenediyl.

4. The compound of claim 1 wherein B is aryldiyl.

5. The compound of claim 1 wherein B is benzenediyl.

6. The compound of claim 1 wherein E is aryldiyl.

7. The compound of claim 1 wherein E is benzenediyl.

8. The compound of claim 1 wherein R_1 is (C_{5-8})cycloalkyl-$(R_8)_q$, cyclic heteroalkyl-$(R_9)_q$, aryl-$(R_8)_q$, heteroaryl-$(R_9)_q$ or NR_5R_6.

9. The compound of claim 1 wherein R_1 is NR_5R_6.

10. The compound of claim 1 wherein R_5 is hydrogen, (C_{1-10})alkanyl-R_7, C(O)H, C(O)-(C_{1-4})alkanyl-R_7, CO_2H, C(O)O-(C_{1-4})alkanyl-R_7, (C_{3-6})cycloalkyl-$(R_8)_q$, cyclic heteroalkyl-$(R_9)_q$, aryl-$(R_8)_q$ or heteroaryl-$(R_9)_q$; wherein cyclic heteroalkyl-$(R_9)_q$ and heteroaryl-$(R_9)_q$ are attached to the nitrogen atom of NR_5R_6 via a ring carbon atom.

11. The compound of claim 1 wherein R_5 is hydrogen, (C_{1-10})alkanyl-R_7 or aryl-$(R_8)_q$.

12. The compound of claim 1 wherein R_5 is hydrogen, (C_{1-10})alkanyl-R_7 or phenyl-$(R_8)_q$.

13. The compound of claim 1 wherein R_6 is hydrogen or (C_{1-4})alkanyl-R_7.

14. The compound of claim 1 wherein R_7 is hydrogen, (C_{1-4})alkoxy-$(R_{10})_s$, C(O)H, C(O)-(C_{1-4})alkanyl-$(R_{10})_s$, C(O)-R_a, CO_2H, C(O)O-(C_{1-4})alkanyl-$(R_{10})_s$, C(O)O-R_a, OC(O)-(C_{1-4})alkanyl-$(R_{10})_s$, OC(O)-R_a, NH_2, NH(C_{1-4}alkanyl-$(R_{10})_s$), N(C_{1-4}alkanyl-$(R_{10})_s)_2$, cyano, $(halo)_{1-3}$, hydroxy or R_a.

15. The compound of claim 1 wherein R_7 is hydrogen, OC(O)-R_a, NH_2, NH(C_{1-4}alkanyl-$(R_{10})_s$), N(C_{1-4}alkanyl-$(R_{10})_s)_2$ or R_a.

16. The compound of claim 1 wherein R_7 is hydrogen, OC(O)-R_a, N(C_{1-4}alkanyl-$(R_{10})_s)_2$ or R_a.

17. The compound of claim 1 wherein R_a is (C_{3-6})cycloalkyl-$(R_{11})_q$, cyclic heteroalkyl-$(R_{12})_q$, aryl-$(R_{11})_q$ or heteroaryl-$(R_{12})_q$.

18. The compound of claim 1 wherein R_a is cyclic heteroalkyl-$(R_{12})_q$ or aryl-$(R_{11})_q$.

19. The compound of claim 1 wherein R_a is pyrrolidinyl-$(R_{12})_q$, piperidinyl-$(R_{12})_q$, morpholinyl-$(R_{12})_q$ or phenyl-$(R_{11})_q$.

20. The compound of claim 1 wherein $(R_8)_q$ is hydrogen, (C_{1-4})alkanyl-$(R_{10})_s$, (C_{1-4})alkoxy-$(R_{10})_s$, C(O)H, C(O)-(C_{1-4})alkanyl-$(R_{10})_s$, CO_2H, C(O)O-(C_{1-4})alkanyl-$(R_{10})_s$, NH_2, NH(C_{1-4}alkanyl-$(R_{10})_s$), N(C_{1-4}alkanyl-$(R_{10})_s)_2$ or halogen.

21. The compound of claim 1 wherein $(R_9)_q$ is hydrogen, (C_{1-4})alkanyl-$(R_{10})_s$, C(O)H, C(O)-(C_{1-4})alkanyl-$(R_{10})_s$, CO_2H or C(O)O-(C_{1-4})alkanyl-$(R_{10})_s$ when attached to a nitrogen atom; wherein $(R_9)_q$ is hydrogen, (C_{1-4})alkanyl-$(R_{10})_s$, (C_{1-4})alkoxy-$(R_{10})_s$, C(O)H, C(O)-(C_{1-4})alkanyl-$(R_{10})_s$, CO_2H, C(O)O-(C_{1-4})alkanyl-$(R_{10})_s$, NH_2, NH(C_{1-4}alkanyl-$(R_{10})_s$), N(C_{1-4}alkanyl-$(R_{10})_s)_2$ or halogen when attached to a carbon atom.

22. The compound of claim 1 wherein $(R_{10})_s$ is hydrogen, C_{1-4}alkoxy, NH_2, NH(C_{1-4}alkanyl), N(C_{1-4}alkanyl)$_2$, $(halo)_{1-3}$ or hydroxy.

23. The compound of claim 1 wherein $(R_{11})_q$ is hydrogen, (C_{1-4})alkanyl, (C_{1-4})alkoxy, NH_2, NH(C_{1-4}alkanyl), N(C_{1-4}alkanyl)$_2$ or halogen.

24. The compound of claim 1 wherein $(R_8)_q$, $(R_9)_q$, $(R_{10})_s$ and $(R_{11})_q$ are hydrogen.

25. The compound of claim 1 wherein $(R_{12})_q$ is hydrogen or (C_{1-4})alkanyl.

26. The compound of claim 1 wherein R_2 is hydrogen, (C_{1-4})alkanyl-R_7, (C_{1-4})alkoxy-R_7, C(O)H, C(O)-(C_{1-4})alkanyl-R_7, CO_2H, C(O)O-(C_{1-4})alkanyl-R_7, NH_2, NH(C_{1-4}alkanyl-R_7), N(C_{1-4}alkanyl-$R_7)_2$, cyano, halogen, hydroxy or R_a.

27. The compound of claim 1 wherein R_2 is hydrogen or (C_{1-4})alkanyl-R_7.

28. The compound of claim 1 wherein R_3 and R_4 are independently hydrogen, (C_{1-4})alkanyl-R_7, C(O)H, C(O)-(C_{1-4})alkanyl-R_7, CO_2H, C(O)O-(C_{1-4})alkanyl-R_7, (C_{3-6})cycloalkyl-$(R_8)_q$ or aryl-$(R_8)_q$ when attached to a nitrogen atom; wherein R_3 and R_4 are independently hydrogen, (C_{1-4})alkanyl-R_7, (C_{1-4})alkoxy-R_7, C(O)H, C(O)-(C_{1-4})alkanyl-R_7, CO_2H, C(O)O-(C_{1-4})alkanyl-R_7, NH_2, NH(C_{1-4}alkanyl-R_7), N(C_{1-4}alkanyl-$R_7)_2$,

cyano, halogen, hydroxy, (C_{3-6})cycloalkyl-$(R_8)_q$, cyclic heteroalkyl-$(R_9)_q$, aryl-$(R_8)_q$ or heteroaryl-$(R_9)_q$ when attached to a carbon atom.

29. The compound of claim 1 wherein R_3 and R_4 are hydrogen when attached to a nitrogen atom; wherein R_3 and R_4 are independently hydrogen, (C_{1-4})alkanyl-R_7 or halogen when attached to a carbon atom.

30. The compound of claim 1 wherein R_3 and R_4 are independently hydrogen, (C_{1-4})alkanyl-R_7 or halogen.

31. The compound of claim 1 wherein R_3 and R_4 are independently hydrogen, (C_{1-4})alkanyl-R_7, chlorine or fluorine.

32. The compound of claim 1 wherein q and s are 1.

33. A compound of Formula (Ia):



Formula (Ia)

wherein

R_{1a} is $NR_{5a}R_{6a}$;

R_{5a} is hydrogen, (C_{1-10})alkanyl-R_{7a} or aryl;

R_{6a} is hydrogen or (C_{1-4})alkanyl-R_{7a};

R_{7a} is hydrogen, OC(O)-R_{a1}, NH_2, NH(C_{1-4}alkanyl), N(C_{1-4}alkanyl)$_2$ or R_{a1};

R_{a1} is cyclic heteroalkyl-$(R_{12a})_q$ or aryl;

$(R_{12a})_q$ is hydrogen or (C_{1-4})alkanyl;

R_{2a} is hydrogen or (C_{1-4})alkanyl-R_{7a};

R_{3a} and R_{4a} are independently hydrogen, (C_{1-4})alkanyl-R_{7a} or halogen; and,

q is 1;

and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

34. A compound of Formula (Ib):



Formula (Ib)

wherein

R_{5b} is hydrogen, (C_{1-10})alkanyl-R_{7b} or phenyl;

R_{6b} is hydrogen or (C_{1-4})alkanyl-R_{7b};

R_{7b} is hydrogen, $OC(O)$-R_{a2}, $N(C_{1-4}$alkanyl$)_2$ or R_{a2};

R_{a2} is pyrrolidinyl-$(R_{12b})_q$, piperidinyl-$(R_{12b})_q$, morpholinyl-$(R_{12b})_q$ or phenyl;

$(R_{12b})_q$ is hydrogen or (C_{1-4})alkanyl;

R_{2b} is hydrogen or (C_{1-4})alkanyl-R_{7b};

R_{3b} and R_{4b} are independently hydrogen, (C_{1-4})alkanyl-R_{7b}, chlorine or fluorine; and,

q is 1;

and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.

35. A compound of Formula (Ib) wherein the compound is selected from the group consisting of

a compound of Formula (Ib) wherein R_{2b} is Me, R_{3b} is Me, R_{4b} is Cl, R_{5b} is H and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is H, R_{4b} is Cl, R_{5b} is propyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is propyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is H, R_{4b} is Cl, R_{5b} is isopropyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is H, R_{4b} is Cl, R_{5b} is isopentyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is isopentyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is H, R_{4b} is Cl, R_{5b} is propyl-$N(Me)_2$ and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is benzyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is heptyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is propyl-Ph and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is decyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is hexyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is ethyl-2-(1-Me)pyrrolidinyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is ethyl-1-pyrrolidinyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is propyl-4-morpholinyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is ethyl-4-morpholinyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is Ph and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is propyl-OC(O)-2-piperidinyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is *t*-butyl and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is *n*-butyl and R_{6b} is Me;

a compound of Formula (Ib) wherein R_{2b} is H, R_{3b} is Me, R_{4b} is Cl, R_{5b} is H and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is Me, R_{3b} is Cl, R_{4b} is H, R_{5b} is H and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is ethyl, R_{3b} is Me, R_{4b} is Cl, R_{5b} is H and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is Me, R_{3b} is Cl, R_{4b} is Me, R_{5b} is H and R_{6b} is H;

a compound of Formula (Ib) wherein R_{2b} is Me, R_{3b} is Cl, R_{4b} is Cl, R_{5b} is H and R_{6b} is H; and,

a compound of Formula (Ib) wherein R_{2b} is Me, R_{3b} is Cl, R_{4b} is F, R_{5b} is H and R_{6b} is H.

36. A method for treating or ameliorating a reactive oxygen species mediated inflammatory disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

37. The method of claim 36 wherein the reactive oxygen species mediated inflammatory disorder is a phosphorylation mediated disorder, a polymorphonuclear leucocyte mediated disorder, a macrophage mediated disorder, a lipopolysaccharide mediated disorder, a tumor necrosis factor-α mediated disorder, acytokine IFN-γ mediated disorder, a interleukin-2 mediated disorder, inflammatory arthritis, potassium peroxochromate arthritis, rheumatoid arthritis, osteoarthritis or Alzheimer's disease.

38. The method of claim 36 wherein the reactive oxygen species is a superoxide, a hydrogen peroxide, a hydroxyl radical or HOCl.

39. The method of claim 36 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 1,000 mg/kg/day.

40. A kit comprising one or more containers containing a compound of claim 1.